Renovaro Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Renovaro.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth28.3%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Enochian stock climbs on US patent for oncology platform

Oct 17

Enochian BioSciences discovers two sets of altered animal data in two of its studies

Jul 01

Is Enochian Biosciences (NASDAQ:ENOB) Using Debt Sensibly?

Jun 28
Is Enochian Biosciences (NASDAQ:ENOB) Using Debt Sensibly?

Enochian Biosciences (NASDAQ:ENOB) Has Debt But No Earnings; Should You Worry?

Feb 20
Enochian Biosciences (NASDAQ:ENOB) Has Debt But No Earnings; Should You Worry?

Enochian Biosciences (NASDAQ:ENOB) Has Debt But No Earnings; Should You Worry?

Oct 30
Enochian Biosciences (NASDAQ:ENOB) Has Debt But No Earnings; Should You Worry?

Enochian Biosciences: A Follow Through For An HIV Cure

Jun 26

Enochian Biosciences shares skyrocket after FDA accepts Pre-IND request for HIV treatment

Jun 14

Do Insiders Own Lots Of Shares In Enochian Biosciences, Inc. (NASDAQ:ENOB)?

Feb 14
Do Insiders Own Lots Of Shares In Enochian Biosciences, Inc. (NASDAQ:ENOB)?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Renovaro has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:RENB - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/2024N/A-116-10-10N/A
6/30/2024N/A-81-11-11N/A
3/31/2024N/A-88-11-11N/A
12/31/2023N/A-41-12-11N/A
9/30/2023N/A-41-12-12N/A
6/30/2023N/A-40-12-12N/A
3/31/2023N/A-107-13-13N/A
12/31/2022N/A-109-12-12N/A
9/30/2022N/A-111-13-13N/A
6/30/2022N/A-113-16-16N/A
3/31/2022N/A-41-26-26N/A
12/31/2021N/A-38-25-25N/A
9/30/2021N/A-35-23-23N/A
6/30/2021N/A-27-21-21N/A
3/31/2021N/A-13-10-10N/A
12/31/2020N/A-11-11-11N/A
9/30/2020N/A-10-12-11N/A
6/30/2020N/A-11-11-10N/A
3/31/2020N/A-6-11-10N/A
12/31/2019N/A-7-10-9N/A
9/30/2019N/A-22-9-9N/A
6/30/2019N/A-18-9-9N/A
3/31/2019N/A-21-9-8N/A
12/31/2018N/A-21-8-7N/A
9/30/2018N/A-6-6-6N/A
6/30/2018N/A-6N/A-4N/A
3/31/2018N/A-4N/A-3N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if RENB's forecast earnings growth is above the savings rate (2.6%).

Earnings vs Market: Insufficient data to determine if RENB's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if RENB's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if RENB's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if RENB's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if RENB's Return on Equity is forecast to be high in 3 years time


Discover growth companies